Nassim Kamar, MD, PhD (Chair)
Head of the Department of Nephrology and Organ Transplantation
Toulouse University Hospital
Toulouse, France (Europe)

Robert A. Montgomery, MD, DPhil, FACS
Professor of Surgery
Director, NYU Langone Transplant Institute
New York, New York (USA)

Camille Nelson Kotton, MD, FIDSA, FAST
Clinical Director, Transplant and Immunocompromised Host Infectious Diseases
Infectious Diseases Division
Massachusetts General Hospital
Associate Professor
Harvard Medical School

Past Chair, Infectious Disease Community of Practice, American Society of Transplantation

Boston, Massachusetts (USA)

Jointly Provided By

Activity Details


1.0 AMA PRA Category 1 Credit

Released: June 27, 2017

Expires: June 27, 2018

1 hour to complete

No registration required



Target Audience

This activity has been designed to meet the educational needs of clinicians and pharmacists who manage cytomegalovirus (CMV) infection and/or antibody-mediated rejection (AMR) in patients who undergo solid organ transplant (SOT).

Learning Objectives

After completing this activity, the participant will demonstrate the ability to:

  1. Incorporate evidence-based treatment protocols and select appropriate therapeutic agents to prevent and treat AMR based on pathophysiology
  2. Outline the significant contribution of human leukocyte antigen (HLA) antibodies and complement deposition in transplant glomerulopathy (TG) and graft loss
  3. Describe the limitations of current CMV preventive and treatment strategies for SOT
  4. Integrate existing and future antivirals into the treatment of CMV infection and/or disease in SOT

Activity Description

This curriculum is designed to assist healthcare professionals in developing AMR and CMV management strategies to improve health outcomes in SOT patients. Healthcare professionals will learn about donor-specific antibodies (DSA), AMR, and TG as important causes of allograft loss as well as emerging AMR therapies that target the humoral immune response. Current state-of-the art CMV antiviral therapeutics, novel antiviral agents, and other modalities including vaccines, and therapeutic antibodies are highlighted.

Disclosure of Conflicts of Interest

Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

  • Robert A. Montgomery, MD, DPhil, FACS, has affiliations with Alexion and Shire (Consulting Fees); and Genentech/Roche and Hansa (Contracted Research/Grants).
  • Camille Nelson Kotton, MD, FIDSA, FAST, has affiliations with Astellas, Cellestis-QIAGEN, Chimerix, Merck, Oxford Immunotec, Roche Diagnostics, and Shire (Consulting Fees); Oxford Immunotec, Roche, Roche Diagnostics, and Shire (Non-CME/CE Services); Oxford Immunotec (Research); and Astellas and Merck (Adjudication Committees).
  • Nassim Kamar, MD, PhD, (Chair) has affiliations with Astellas and Novartis (Consulting Fees).
RMEI Medical Education, LLC
  • Katie Barry has no affiliations with commercial interests to disclose.
  • Sherri Kramer, MD, has no affiliations with commercial interests to disclose.

Postgraduate Institute for Medicine
The following PIM planners and managers, Judi Smelker-Mitchek, RN, BSN, Trace Hutchison, PharmD, Samantha Mattiucci, PharmD, CHCP, and Jan Schultz, MSN, RN, CHCP, have nothing to disclose.

Physician Continuing Medical Education

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Postgraduate Institute for Medicine and RMEI Medical Education, LLC. The Postgraduate Institute for Medicine is accredited by the ACCME to provide continuing medical education for physicians.

The Postgraduate Institute for Medicine designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

How to Receive Credit

By reviewing the course content and successfully completing the post-test and evaluation, physicians, nurse practitioners, and physician assistants are entitled to receive up to 1.0 AMA PRA Category 1 Credit(s)™. A statement of credit will be available to print immediately. Users must:

  • Read the learning objectives and faculty disclosures.
  • Participate in the activity.
  • Complete the activity evaluation.

Physicians, nurse practitioners, and physician assistants who successfully complete the post-test and evaluation will receive CME credit. You must score 75% or higher on the post-test to receive credit for this activity. All other participants who successfully complete the post-test and evaluation will receive a certificate of participation.

Statement of Commercial Support

This activity is supported by an independent educational grant from Shire.


Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients' conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Course Viewing Requirements

Pro-CME recommends using the latest versions of these supported browsers: Google Chrome, Microsoft Internet Explorer, Mozilla Firefox, Safari. Depending on your browser of choice, additional software, such as Adobe Reader® and Adobe® Flash® Player may be required.

Suggest a CME Activity

Please provide below the URL and description of an activity you would like to add to OpenCME. You are welcome to add activities as often as you like. To prevent spam or other abuse, activities are reviewed by our editorial team before appearing on OpenCME.

OpenCME for Publishers

Please use the form below if you would like to offer your website visitors high-quality CME content by adding the OpenCME Widget to one or more of your pages.

Start Activity

Select your specialty

You must select a specialty

Send Email to a Colleague

To share this activity with one or more colleagues, enter their e-mail addresses below. To include a personal message, simply overwrite the suggested text below.

(So your recipient knows it's from you.)
Enter multiple recipients separated by a space.
Optionally, replace/modify in the box above the message that will be sent to your colleague(s) with a link to download this app.